◆　Jinerlun Injection is one of the CMS self-owned products, manufactured by Kangzhe (Hunan) Medical Co., Ltd. and marketed by Shenzhen Kangzhe Pharmaceutical Co., Ltd.

　◆　It is an off-patent generic pharmaceutical based on the active ingredient Naloxone Hydrochloride. As antagonist of opium receptor, it is targeted to relieve the respiratory depression caused by opioid combined anesthesia, and to treat opiums overdose and acute alcohol intoxication. It is under National Basic Insurance Drug List, under category A.

　◆　CMS started the manufacturing and sale of Jinerlun Injection in 1997. Sales of Jinerlun Injection increased after its launch. By the end of 2004, the sales have ever reached over 100 million RMB. We expect to maintain a piece of market share relying on Jinerlun’s brand loyalty and sales and marketing professionals' effort.